Insulin getting assembled into a mature form was the major challenge in commerical insulin production by rDNA technology. How did Eil Nilly Company found a solution to this problem ?

Explanation

**Step-by-Step Solution:**

1. **Understanding the Problem**: The major challenge in commercial insulin production using recombinant DNA (rDNA) technology was the assembly of insulin into its mature form. Insulin is produced as a pro-hormone that includes three chains: the A chain, the B chain, and the C-peptide. The mature form of insulin consists only of the A and B chains, with the C-peptide removed.

2. **Background on Insulin Production**: Traditionally, insulin was extracted from the pancreases of slaughtered animals (cattle and pigs). However, this method posed problems, as patients often developed allergies and reactions due to the foreign proteins present in animal-derived insulin.

3. **The Role of Eli Lilly Company**: In 1983, the Eli Lilly Company sought to produce human insulin using rDNA technology. They aimed to create a method that would allow for the production of insulin that was identical to the human form, thus reducing the risk of allergic reactions.

...